Addition of sodium butyrate to the culture medium of the human hepatoma cell line Hep G2 resulted in a time-and dosedependent increase in the secretion of apolipoprotein A-I (apo A-I) and apolipoprotein BlOO (apo B100). After a 24 h preincubation period, a 2.4-and 2.2-fold increase in the secretion of apo A-I and apo B100 respectively was obtained during the next 24 hin-the presence of 2 mM-sodium butyrate. Secretion of albumin, fibrinogen or [35S]methionine-labelled newly synthesized proteins was unaffected or only marginally affected, indicating that the effect of butyrate on apo A-I and apo B100 is not part of a general effect on protein synthesis and secretion. In structure-function studies, butyrate was found to be the most potent inducer among various straight-chain carboxylic acids. Hydroxylated, aminated and otherwise modified butyrate derivatives were inactive. The enhanced accumulation of apo A-I and apo BIO0 in the culture medium could not be explained by changes in the uptake and degradation of the synthesized apolipoproteins or by alterations in the secretion of possible intracellular pools. In addition, [35S]methionine incorporation studies indicated that synthesis and/or secretion of newly synthesized apo A-I and apo B100 is enhanced in the presence of butyrate. The apo A-I mRNA level was increased 2.3-fold upon treatment with 2 mM-butyrate for 48 h, suggesting regulation at (post-)transcriptional level. In contrast, no change in the level of apo B100 mRNA in butyrate-treated cells was observed, indicating regulation at translational or co-or post-translational level. We propose that the effect of butyrate on the secretion of apo A-I and apo B100 by Hep G2 results from two different regulatory mechanisms.
INTRODUCTION
Plasma levels of low-density lipoprotein (LDL) cholesterol and high-density lipoprotein (HDL) cholesterol are, respectively, positively and negatively related to the development of atherosclerosis [1] [2] [3] . The proteins which are part of these lipoproteins, i.e. the apolipoproteins, are also used in risk assessment for cardiovascular disease. The plasma levels of apolipoprotein B O00 (apo B100) and apolipoprotein A-I (apo A-I) have been reported to be even more discriminatory in determining the risk of developing coronary heart disease than the cholesterol concentration in the lipoprotein from which they are a constituent, i.e. LDL and HDL [4] [5] [6] .
A vast number of reports describe regulation of the synthesis and secretion of apo A-I and apo B100, as a way of altering the amounts and composition of lipoproteins in the blood. Since the liver is the central organ in the metabolism of these two apolipoproteins, many of the studies were done with perfused livers and primary cultures of hepatocytes from animal origin, owing to the limited availability of human liver. More recently, the human hepatoma cell line Hep G2 has been used as a model to study the apolipoprotein and lipoprotein synthesis and catabolism in human hepatocytes. This cell line has been shown to synthesize a number of apolipoproteins, including apo A-I and apo BiO [7] . Apo A-I is secreted as a HDL-like particle, but is also found in a lipid-poor or lipid-free form, whereas apo B100 is secreted as a constituent of a LDL-like particle enridhed in triacylglycerol [8] . In this respect, secretion of apo B1OO differs from the situation in vivo, possibly as a result of the deCreased amount of smooth endoplasmic reticulum in Hep G2 clls [8] , which may lead to a defective lipoprotein assembly and secretion in these cells [9] . Furthermore, the availability of fatty acids may be of importance [10] . Nevertheless, the Hep G2 cell line was found to be a suitable model for investigating the regulation of the synthesis and/or secretion of apo A-I and apo B1OO in response to lipoproteins [11, 12] , fatty acids [9, 10, [13] [14] [15] , insulin [9, 13, 14] and steroid hormones [16] .
In many of these reports, supply of lipids and changes in the assembly of lipoproteins are thought to be responsible for the alterations in the synthesis and secretion of apo A-I and apo B100. In a search for compounds which may affect the synthesis and/or secretion of these two apolipoproteins by another regulatory mechanism, we investigated the effect of butyrate. Butyrate is known to induce specific alterations in different cell types, including hepatoma-cell lines and hepatocytes (for a review see Kruh [17] ). One of the most evident changes brought about is the hyperacetylation of histones [18] , owing to inhibition of the enzyme histone deacetylase [19] . This process has been shown to affect gene expression [20] [21] [22] [23] .
In this paper we describe the effects of butyrate on apo A-I and apo B1OO secretion by Hep G2 cells. The secretion of these proteins into the medium was found to be enhanced more than 2-fold upon incubation with butyrate. This increase was accompanied by a comparable stimulation of the apo A-I mRNA, without a change in the apo B1OO mRNA level. 
MATERIALS AND METHODS

Cell culture
The established Hep G2 cell line, derived from a human liver tumour, was obtained from Dr. B. B. Knowles (Wistar Institute of Anatomy and Biology, Philadelphia, PA, U.S.A.). The cells were cultured as described [24] at 37°C, under air/CO2 (19: 1), in 25 cm2 flasks containing 0.1-0.2 ml of culture medium/cm2. Standard medium used was DMEM supplemented with 20 mmHepes, 1O mM-NaHCO3, 10% (v/v) FBS (heat-inactivated for 30 min at 56°C), 2 mM-glutamine, penicillin (100 units/ml) and streptomycin (100 ug/ml). The medium was renewed twice a week. At 4-5 days before the start of the experiment, the cells were treated with trypsin and transferred to six-well-cluster plates (10 cm2/well; Costar, Cambridge, MA, U.S.A.) with a split ratio of 1: 6, and were grown to confluency before starting the experiments,, in order to study the effect of butyrate on protein synthesis, other than due to arrest of cell growth.
Except where otherwise described, the effect ofsodium butyrate and related analogues was studied over a 24 h period, after a 24 h preincubation with the same compound at the same concentration. At the end of the incubation period, medium was collected and centrifuged for 1-2 min in an Eppendorf centrifuge (type 5414) to remove detached cells and debris. The supernatant was frozen immediately in liquid nitrogen and stored at -20°C, until measurement of apo A-I and apo BiO concentrations. Cells were washed three times with cold phosphate-buffered saline (sodium/potassium phosphate buffer; 11 mm, pH 7.5) containing 150 mM-NaCI] and were harvested by scraping in water. The cellular protein was determined as described by Lowry et al. [25] . E.l.i.s.a. of apo A-I Specific IgGs against human apo A-I were isolated from goat antiserum (raised in our Institute) by affinity chromatography using purified apo A-I cross-linked to Sepharose 4B (Pharmacia), as described by Bury & Rosseneu [26] . Part of the isolated anti-(apo A-I) IgG was conjugated to horseradish peroxidase (EC 1.11.1.7) by the SPDP [N-succinimidyl 3-(2-pyridyldithiopropionone)] method, essentially according to the Pharmacia procedure. Immunoblotting of human serum and FBS after SDS/PAGE showed that anti-(apo A-I) IgG was monospecific for human apo A-I.
The isolated anti-(apo A-I) and the peroxidase-anti-(apo A-I) conjugate were used in a 'sandwich' e.l.i.s.a., in accordance with the procedure described by Bury & Rosseneu [26] , with a few modifications. In short, polystyrene micro-titre plates ('Nunc Immuno' plates, 'high-binding' quality; Intermed, Roskilde, Denmark) were coated with anti-(apo A-I) IgG (10 lug/ml in phosphate-buffered saline) containing NaN3 (1 g/l) (120 ,l/well). [27] .
The working range of the e.l.i.s.a. is 20-150 ng/ml and as little as 10 ng of apo A-I/ml can be detected. The standard curves for purified apo A-I, apo A-I in human serum, and apo A-I in the medium of Hep G2 cell cultures were parallel. Apo A-I concentrations in sera measured by the e.l.i.s.a. were identical with values found with radial immunodiffusion [28] . E.l.i.s.a. of apo B100
Specific IgGs against human apo B100 were isolated from rabbit antiserum (raised in our Institute) by affinity chromatography, exactly as described above for the purification of anti-(apo A-I) IgG, by using purified apo E-free LDL cross-linked to Sepharose 4B (Pharmacia). LDL was purified from human serum by density-gradient ultracentrifugation as described by Redgrave et al. [29] . The LDL was aspirated from the gradient between densities of 1.030 and 1.050 g/ml, adjusted with KBr to a density of 1.21 g/ml, layered under a KBr solution in water, of the same density, and ultracentrifuged to purify further and to concentrate LDL. SDS/PAGE of the LDL showed that apo B1OO was the only protein present in the isolated LDL, as determined by silver staining as described by Paleologue et al. [30] . SDS/PAGE was performed under reducing conditions by the method of Laemmli [31] , with resolving gels containing a gradient of 4-20 % (w/v) acrylamide and stacking gels of 3.5 % (w/v) acrylamide. Immunoblotting of human serum and FBS, after SDS/PAGE, showed that the isolated antibodies were monospecific for human apo B.
Part of the isolated anti-(apo B) IgG was conjugated to horseradish peroxidase and used together with anti-(apo B) in a 'sandwich' e.l.i.s.a. The e.l.i.s.a. procedure was similar to that for apo A-I, except that the final IgG concentration in the peroxidase-anti-(apo B) conjugate was 50 ng/ml. The working range of the assay was 100-1000 ng of apo B/ml, and as little as 50 ng/ml could be detected. The standard curves for LDL (isolated from human serum by density-gradient ultracentrifugation), apo B in human serum, and apo B in medium of Hep G2 cells were parallel. Apo B concentrations measured in sera by the e.l.i.s.a. showed a linear correlation with values found with radial immunodiffusion [32] .
Association and degradation of apo B100 (LDL) and apo A-I (HDL) Association and degradation of HDL and LDL by Hep G2 cells were measured as described by Dashti et al. [33] and Goldstein et al. [34] respectively, over a 24 h period. The concentration of '25I-labelled apo B1OO (in LDL) and apo A-I (in HDL) added to the medium were 2.0 and 2.5 ,ug/mg of cell protein respectively, as measured by the e.l.i.s.a. procedure. These concentrations are comparable with the amounts of apo A-I and apo B1OO secreted by Hep G2 cells during a 24 h incubation in control medium.
Measurement of the secretion of albumin and fibrinogen Accumulation of albumin in the medium of Hep G2 cell cultures was measured by rocket immunoelectrophoresis by the method described by Laurell [35] by using rabbit anti-(human albumin) antiserum (Dakopatts, Glostrup, Denmark). Accumulation of fibrinogen in the medium was measured by an e.l.i.s.a. procedure [36] . Degradation of fibrinogen was prevented by adding trasylol and heparin to the medium, both at a concentration of 10 units/ml. This addition did not affect basal or butyrate-stimulate,d secretion of apo A-I and apo B100 in the culture medium.
Butyrate stimulates secretion of apo A-I and apo BlOO Protein synthesis
Overall secretion of newly synthesized proteins was measured essentially as described by Kooistra et al. [37] . The metabolically radiolabelled proteins secreted in the medium were analysed by SDS/PAGE under reducing conditions as described above.
Protein molecular-mass standards (Bio-Rad, Richmond, CA, U.S.A.) were used for calibration of the gel. For autoradiography the gel was treated with an autoradiography enhancer (En3Hance; NEN DuPont, Boston, MA, U.S.A.) in accordance with the manufacturers' instructions, dried and placed on X-ray film (Ko'dak X-Omat AR films; Eastman-Kodak Co., Rochester, NY, U.S.A.), and stored at -80°C for the appropriate time.
RNA hybridization
Total RNA was isolated from Hep G2 cells by the method of Chomczynski & Sacchi [38] . After washing the RNA pellets with 70 % (v/v) ethanol, RNA samples were dissolved in water. The RNA concentration in each sample was determined spectrophotometrically, assuming that one A260 unit is 40 ,ug of RNA/ml.
Equal amounts of total RNA from different incubations were fractionated by electrophoresis in a 0.8 % (w/v) agarose gel containing 1 M-formaldehyde, and transferred to Hybond N (Amersham) in accordance with the manufacturer's instructions.
RNA blots were hybridized with different probes at-65 0C in a sodium phosphate buffer (0.5 M, pH 7.5), containing 7 % (w/v) SDS and 1 mM-EDTA. DNA fragments used as probes were isolated from low-melting-point agarose [39] . One blot was hybridized with 25 ng of probe, labelled by the random-primer method (Multi-prime, Amersham) to approx. 2 x 108-109 c.p.m./,ug of DNA.
After hybridization, the blots were washed twice with 2 x SSC/0.1 % SDS (30 min at 65°C) (I x SSC = 0.15M-NaCI/0.015 M-sodium citrate, pH 7.0), twice with 1 x SSC/0.1 % SDS (30 min at 65°C), and twice with 0.1 x SSC/0.1 % SDS (30 min at 65°C), successively. The blots were exposed to Hyperfilm MP (Amersham), together with an intensifying screen (Eastman-Kodak Co.), for 15-75'h at -80 'C. For quantification of the relative amounts of mRNA, the autoradiographs were scanned with a Shimadzu CS 910 chromatograph scanner, and areas under the peaks were integrated and plotted with the aid of a data processor (Shimadzu Corp., Kyoto, Japan). The mRNA levels were quantified by using three different amounts of total RNA loaded on the gel, giving a linear relation between the specific mRNA signal and the amount of RNA applied. For apo A-I and albumin mRNA, linearity was present with 1.5, 3 and 6 jug of total RNA. For apo B100 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA there was linearity with 3, 6 and 12 ,ug of total RNA.
The following DNA fragments were used as probes in the hybridization experiments: a 2.2 kb PstI fragment of the human apo A-I genomic DNA (kindly provided by Dr. S. E. Humphries [40] ), a 2.7 kb HindIII fragment located at the 3' end of human apo B100 cDNA (kindly provided by Dr. J. Scott [41] ), a 740 bp HindlII/PstI fragment located at the 3' end of human serum albumin cDNA, and a 1.2 kb PstI fragment of rat GAPDH cDNA (kindly provided by Dr. R. Offringa [42] Vol. 278 in subsequent experiments the effect of butyrate on Hep G2 cell cultures was studied over a 24 h period, after a 24 h preincubation period in the presence of the same butyrate concentration.
As shown in Fig. 2 , addition of increasing amounts of butyrate resulted in an increase in the secretion of apo A-I and apo B1OO in the medium of Hep G2 cell cultures. The effects on apo A-I and apo B1OO were comparable in magnitude for the various butyrate concentrations. A significant increase was only found with concentrations of 1 mM-sodium butyrate or higher (paired t test, P < 0.05). Judging from the changes in cell morphology and loss of cells from the culture dishes, butyrate concentrations > 3 mm were cytotoxic to Hep G2 cell cultures. Therefore, further experiments were performed at a concentration of 2 mmbutyrate. At this concentration no adverse effect was observed on the cell morphology, on the cell protein present in the culture dishes at the end of the incubation, or on the release of the cytoplasmic enzyme lactate dehydrogenase.
Butyrate stimulates the secretion of newly synthesized apo A-I and apo B100
Since Hep G2 cells are capable of binding and internalizing LDL [43] and HDL [33] , inhibition of the uptake and degradation might have caused the observed changes in the accumulation of apo B1OO and apo A-I in the culture medium. The results listed in Table 1 for the accumulation and for the binding and degradation of apo B1OO and apo A-I show that uptake and degradation is far smaller than the accumulation in the medium of both apolipoproteins over a 24 h period. Addition of butyrate (2 mM) to the medium resulted in decreased binding and degradation of apo A-I and apo B100, but this does not explain the increases found in the accumulation.
In addition, changes in the secretion of possible intracellular storage pools of apo A-I and apo B1OO can also not explain the incubation of Hep G2 cells in standard medium, the apo A-I and apo B1OO concentrations were measured in the culture medium and in the cells. The cells were solubilized in phosphate-buffered saline containing 0.5% Triton X-100. Apo A-I and apo B1OO were measured by the e.l.i.s.a. procedure (addition of Triton X-100 had no effect on the e.l.i.s.a. results). For apo A-I and apo B1OO we found that 95 % and 85-90 %, respectively, of the total amount of the apolipoproteins was present in the medium. These experiments indicate that the effect of butyrate on the accumulation of po A-I and apo B100 is caused by increases in the secretion of newly synthesized apolipoproteins. Specificity of the stimulation of apo A-I and apo B100 secretion by butyrate To see whether the effect of butyrate on the secretion of apo A-I and apo B1OO is part of a general effect of butyrate on Hep G2 cell cultures, secretion of albumin and fibrinogen in the culture medium was measured. The results are shown in Table 2 . Only minor differences were found for the secretion of albumin and fibrinogen upon incubation of cells in standard medium with 2 mM-butyrate.
In addition to the effect of butyrate on the albumin and fibrinogen secretion, the total protein secretion by Hep G2 cell cultures was studied by using [35S]methionine incorporation in newly synthesized and secreted proteins. Little effect was observed on the secretion of total newly synthesized proteins (see Table 2 ). To explore the possibility that butyrate may alter the pattern of the proteins secreted into the culture medium, the medium of the experiment described above was separated by SDS/PAGE and autoradiographed (Fig. 3) . Hep G2 cells incubated with butyrate secreted a similar pattern of proteins in the culture medium as in control cells, except for a few proteins (indicated by the arrows in Fig. 3 ) which showed an altered intensity. After specific immunoprecipitation, the proteins with molecular masses of approx. 500 and 28.5 kDa were identified as apo BI00 and apo A-I respectively. Structural specificity studies Table 3 shows the effects of various butyrate analogues, all tested at a concentration of 2 mm, on the secretion of apo A-I and apo Bl00 in the medium of Hep G2 cell cultures. The results for the various butyrate analogues used were comparable for apo A-I and apo BlOO. Butyrate was the most potent inducer. Other straight-chain unsubstituted carboxylic acids, propionate (C3) and valerate (C5), also gave a significantly increased secretion of both apolipoproteins. They were, however, less effective than butyrate. The straight-chain carboxylic acids acetate (C2) and hexanoate (C,) were either ineffective or only marginally effective.
No effects were found with hydroxylated or aminated butyrate derivatives, isobutyrate (the branched-chain analogue of butyrate), crotonate (which contains a double bond between the C-2 and C-3 as compared with butyrate), butanol, ybutyrolactone (intramolecular lactone), 2-oxobutyrate and succinate, all differently oxidized C4 analogues.
Effect of butyrate on apo A-I and apo B100 mRNA levels To observe whether the accelerated secretion of apo A-I and apo BlOO results from changes in mRNA levels, the effect of butyrate on the mRNA level ofboth apolipoproteins was assessed by Northern-blot hybridization (Fig. 4) 
DISCUSSION
In this paper we show that butyrate increases the secretion of apo A-I and apo B1OO by the human hepatoma cell line Hep G2, in a time-and dose-dependent way. This is not due to a decreased uptake and degradation of HDL (apo A-I) and LDL (apo Bf100) in the presence of butyrate, nor to differences in the secretion from possible intracellular pools of apo A-I and apo B100. It indicates that butyrate stimulates the synthesis and/or the secretion of newly synthesized apolipoproteins. This was confirmed by the [35S]methionine incorporation experiment (Fig. 3) .
As illustrated by the secretion of albumin, fibrinogen and [35S]methionine-labelled proteins, the effect of butyrate on apo A-I and apo B1OO was not part of a general effect on proteins secreted by Hep G2 cells. In addition, the stimulatory effect was specific for butyrate. Only propionate and valerate, the C3 and C5 straight-chain carboxylic acids respectively, induced a significant increase in the secretion of apo A-I and apo B100, although less markedly than butyrate. Similar quantitative differences were found with butyrate and a limited set of other straight-chain carboxylic acids tested on various functions in different cell types [17] . Kooistra et al. [37] studied a large set of butyrate analogues for their effect on the tissue plasminogen activator ('t-PA') synthesis by cultured human endothelial cells. The stimulatory effect on this synthesis was in the order butyrate > valerate > propionate. Our results on structure-function relationship are comparable with the reports mentioned above, suggesting that a common mechanism may be responsible for the effects described.
Such a mechanism may be acetylation and deacetylation of histones, which play a role in the regulation of the expression of specific genes by introduction of changes in the chromatin structure. Butyrate treatment of HeLa cells and Friend erythroleukaemia cells [18] resulted in a hyperacetylation of the histones. Similar findings were described for a rat hepatoma cell line (HTC) by Sealy & Chalkley [19] . These authors showed that this hyperacetylation was due to inhibition of the enzyme histone deacetylase by butyrate. An effect of butyrate on gene expression may also be an explanation for the enhanced secretion of apo A-I by Hep 02 cells.
Another possibility may be interference by butyrate with lipid synthesis and secretion. It has been reported that butyrate stimulates synthesis of fatty acids and triacylglycerols in rat hepatocytes [44, 45] and hepatoma cells [46] , with only a marginal effect on sterol synthesis [44, 45] . Supply of triacylglycerols or fatty acids leading to an increased triacylglycerol synthesis did, however, not affect apo A-I secretion [13, 47, 48] by hepatocytes or the apo A-I mRNA level [14] in Hep G2 cells. Furthermore, apo A-I secretion was variably affected by cholesterol-rich liposomes and only slightly increased upon incubation with /,-VLDL [11] , indicating that the supply of cholesterol has no or little effect on apo A-I secretion by Hep G2 cells. This is supported by the absence of an effect of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor CS-5 14 on apo A-I secretion [49] and the increase of only 20% in the apo A-I mRNA level during supplementation of the medium with LDL [12] . In our experiments with butyrate we found a 2.3-fold increase in the apo A-I mRNA level after 48 h, which is comparable with the 2.4-fold increase in the secretion. In addition, the accelerated accumulation of apo A-I, as shown in Fig. 1 , is in agreement with the time course of the effect found on the mRNA level (Fig. 4b) . These findings, together with the above-mentioned observations, do not favour the hypothesis that butyrate stimulates apo A-I secretion via a possibly altered lipid secretion, and suggest an effect of butyrate on gene expression. However, an increase in the stability of the apo A-I mRNA cannot be excluded.
Although the overall effects of butyrate and butyrate analogues on the secretion of apo A-I and apo B1OO were similar, this need not result from the same regulatory mechanism. In contrast with apo A-I, butyrate did not affect the apo B100 mRNA level. Synthesis of apo B100 and/or secretion of newly synthesized apo BlOO was increased in butyrate-treated Hep G2 cells. After separating the culture medium, by density centrifugation, into lipoproteins (d < 1.20) and a lipid-poor or lipid-free fraction (d > 1.20), we found that cells incubated with or without butyrate secreted apo B100 only as a constituent of lipoproteins. Apo A-I was found both in the lipoprotein-rich and in the lipid-poor or lipid-free fraction (results not shown). The latter finding may be explained by dissociation of apo A-I from the native discoidal lipoprotein particle after secretion, owing to a decreased affinity of apo A-I for this particle in the absence of lecithin: cholesterol acyltransferase activity or as the result of direct secretion of lipidpoor apo A-I in the medium itself [8] . The increase in the secretion of apo A-I upon butyrate treatment was seen in both fractions. The observed distribution of apo B1OO over lipoproteins and of apo A-I over the lipoprotein-rich and the lipidpoor fraction, secreted by Hep G2 cells, was in accordance with results of Thrift et al. [8] . The increased secretion of apo BI00 may be regulated translationally (increased synthesis) or by the co-or post-translational processing of apo B1OO or assembly of apo B1OO into the lipoprotein. This co-or post-translational regulation has been described as important in determining the amount of apo BIOO secreted by Hep G2 and hepatocytes [50] [51] [52] [53] . Lipid supply, i.e. fatty acid, triacylglycerols and cholesterol, was found to be of particular importance in this process by increasing apo B1OO secretion [9, 15, 54] . Although we did not measure lipid synthesis, the finding that butyrate stimulates fatty acid and triacylglycerol synthesis in rat hepatocytes and hepatoma cells may provide a plausible explanation for the enhanced secretion of apo B100. However, as we show in the structurespecificity studies, propionate also increased the apo B1OO secretion significantly, and acetate had no effect. Nishina et al. [44] and Wright et al. [55] reported that propionate inhibited fatty acid synthesis and had no or an inhibitory effect on sterol synthesis, whereas acetate stimulated fatty acid synthesis and inhibited sterol synthesis [44, 56] . These conflicting data suggest that alterations in lipid synthesis need not be the only explanation for the increased apo B1OO secretion.
Butyrate is present in human nutrition, e.g. dairy products, but it is unlikely that it is a suitable agent to affect apo A-I and apo B1OO secretion by hepatocytes in vivo. Plasma concentrations of butyrate remain low in general, because it is metabolized rapidly. However, the experiments with butyrate provide interesting data which may lead to a better understanding of the mechanism which controls the synthesis and secretion of apo A-I and apo BI00 by hepatocytes.
